Life Sciences Archive » November, 2011

Life Sciences - November, 2011

154 articles

• Boehringer Loses Bid To Decertify Sales Rep OT Action
• AAI Presses FTC To Block Express Scripts' Buy Of Rival
• Investors Sue Abbott Over $1.5B Depakote Settlement Tab
• Genentech Settles FCA Suit Over Cancer Drug For $20M
• Unsealed FCA Suit Accuses Pfizer Of Off-Label Marketing
• Pfizer Told To Cough Up Docs In Drug Marketing Action
• Pharmasset Investor Challenges $11B Gilead Deal
• Health Canada Bans Avastin For Breast Cancer Treatment
• Allergan Sues Apotex Again Over Generic Pinkeye Drug
• Dearth Of A 'Sales'man
• The Changing Scope Of Expert Witness Disclosures
• Lens Maker Sued Over Hazy Quality Control Standards
• The Downside To An Aggressive Defense
• FDA Chemist Settles Insider Trading Suit For $4M
• Producer Pleads Guilty To $2.6M Insider Trading Scheme
• Facebook Takes Responsibility For Merck Mix-Up
• AMO, Consumers Settle Contact Lens Marketing Action
• Pharmacies Turned Away By High Court In W.Va. Drug Suit
• ArthroCare To Pay $74M To End Stock Inflation Action
• Fordham Professor To Lead Fosamax Settlement Talks
• Supreme Court To Rule On GSK Reps' OT Status
• Giving Credit Where Credit Is Due
• Allergan Investors Sue Board Over Tax Tab For Exec Pay
• 8th Circ. Won't Rehear Heart Defect Drug Competition Suit
• Merck KGaA Accuses Merck & Co. Of Facebook Ambush
• Warner Targets Mylan's Plans For Generic Contraceptive
• Chattem Targeted Over Mouthwash Anti-Plaque Claims
• What Sets SciClone's FCPA Derivative Suit Apart
• Complying With Restrictions On Multisite Data Use
• Smith & Nephew Says Hologic Cut Into Its Surgical Patent
• Graceway Cleared To Sell Assets To Medicis For $455M
• EU Agency Calls For Recall Of US-Made Cancer Drugs
• Merck To Pay Nearly $1B To Settle Vioxx Marketing Claims
• FDA Chides Mylan Over Puerto Rico Plant Violations
• More Reasons To Discount Adverse Event Reports
• Darvocet, Darvon Suits Must Be Nixed After Mensing: Lilly
• Mylan Asks Fed Circ. To End Doryx ANDA Injunction
• Ropes & Gray Helps Pfizer Buy Anti-Scar Drug Co.
• Siemens Targeted Over Medical Scan Patent
• Is Inequitable Conduct Still A Viable Defense?
• Synthes Execs Sentenced Over Bone Cement Trials
• Novartis, Mylan Settle Feud Over Generic Vivelle-Dot
• Teva, Bayer Settle Dispute Over Levitra Patents
• 7th Circ. Affirms Lovenox Kickback Case Conviction
• Pfizer To Settle FCPA Bribery Probe For $60M
• Actelion To Appeal $415M Verdict Over CoTherix Buy
• Takeda Targets Rival Over Generic Diabetes Drug
• Duane Morris Woos 2 Deals Experts For Calif. Offices
• Looking For Loopholes In PLIVA V. Mensing
• Gilead Expands Hep C Efforts In $11B Skadden-Led Buy
• Valeant Buys INova From PE Firms For $688M
• Ex-Synthes Execs To Be Sentenced For 'Rogue' Trials
• Novartis Bone Drug Suit Falls Under NJ Damages Law: Court
• Bankrupt Graceway Faces Copyright Suit Over Drug Promos
• FrontPoint's Skowron Gets 5 Years For Insider Trading
• Class Action Attys Awarded $7M For 'Mona Lisa'-Like Work
• Fighting Reverse Payments In The Drug Industry
• FDA Bars Avastin's Use As Breast Cancer Treatment
• Kirkland Helps Bain Repurchase Physio-Control For $487M
• Watson Ducks Ky. Drug Price Inflation Suit
• Health Benefit Manager Expands Base In $250M Deal
• FDA Withholding Evidence In Birth Defects Suit: Attys
• Ex-Abbott Drug Rep Exempt From OT, Judge Says
• CooperVision Widens Contact Lens Recall
• Cigna Offers 15M Shares To Fund $4B HealthSpring Buy
• Sandoz, States Settle Drug Inflation Claims For $150M
• The Truth Is Out There, But Not Always On The Label
• FTC Nominees Weigh In On Pay-For-Delay Deals, Privacy
• Sens. Blast FDA's 'Slow' Device Approval Process
• Supplement Co. Accused Of Hiding Risky Ingredient
• APP Takes Angiomax Patent Extension Fight To Fed. Circ.
• Wyeth Resolves False Ad Fight Against Sun In 6th Circ.
• China Fines Cos. $1M Over Drug Ingredient Monopoly
• Olympus Investor Sues Over Merger Fee Scandal
• Blue Cross Sued Over 'Bait And Switch' Deductible Hikes
• Bard Ends Vessel Graft Patent Feud With Endologix
• Patent Group Rips America Invents In Tylenol Marking Suit
• Examining AIA's High-Speed Inter Partes Review System
• Merck Strikes Deal With Fla., NY, SC Over Vioxx Claims
• Anadys Shareholders Challenge $230M Sale To Roche
• Allergan Takes Aim At Lupin Over Lumigan ANDA
• Novartis Backs Medical Test Patent In High Court
• Failure-To-Warn Claims Need Fail-Proof Evidence In NJ
• ITC Refuses To OK Amgen, Roche Anemia Drug Deal
• FDA Unveils New Rules To Speed Up Medical Device Studies
• MSNBC Sued For Profits From Film About MJ's Doctor
• FDA Warns Int'l Isotopes Over Unapproved Thyroid Drug
• Fed. Circ. Nixes Teva Bid To Halt Generic Seasonique
• Ex-DHB Directors Strike $1.6M Deal To End SEC Fraud Suit
• J&J Wants Rivals' Marketing Data In Omnicare FCA Row
• Tightening The Noose Around TPP Claims
• Galderma Targets Amneal's Generic Rosacea Treatment
• Proskauer's New Beijing Office To Focus On M&A, PE
• HIPAA Enforcement Lacks Teeth Despite Changes: Panel
• Medco, Investors Settle Over $29B Express Scripts Merger
• DOJ Subpoenas Merck Over Avelox, Integrilin Marketing
• Top Female Deal Maker: Mayer Brown's Jodi Simala
• Abbott Can't Escape Suit Over Humira's Cancer Risks
• Frazier, Vivo Add To Rempex's $67.5M In Fundraising
• Merck Settles ERISA Suit Over Vioxx Claims For $50M
• Affymax To Pay J&J Unit $13M In Anemia Drug IP Dispute
• Back To The Future With Medicare Bundled Payments
• Ore. Says McKesson Artificially Inflated Drug Prices
• Toxic Torts: Designation For Causation
• Case Study: Turek V. General Mills
• GSK Prodded Toward Mediation In Avandia MDL
• Calif. Pharmacies Sue Pfizer, Ranbaxy Over Lipitor Deal
• Warner Chilcott Targets Cadila Over Generic Asacol
• Sens. Probe Cigna, Quest, Others Over Lab Kickbacks
• St. Jude Vascular Device Patent Protected By Law: Judge
• 9th Circ. Keeps Investor Class Intact In Anemia Drug Fight
• Amylin, Lilly Wrap Up Diabetes Drug Alliance, Lawsuit
• Goodwin Helps TA Snag Senior Whole Health For $135M
• Top Female Deal Maker: Dewey & LeBoeuf's Jane Ross
• Savient Investor Asks 2nd Circ. To Reopen Fraud Case
• Hines Drops $160M For Boston-Area Office Park
• AstraZeneca Indicted In Serbia Over Doctor Payments
• Federal Preemption For Generic OTC Drugs?
• GSK, Colgate Put Toothpaste Nurdle IP Battle Behind Them
• Judge Finds Valeant's Antidepressant Patents Valid
• Pfizer, Aurobindo Reach Accord In Lipitor Patent Case
• CVS, KV Resolve $100M Suit Over Drug Supply Contract
• Knee Device Maker Sues Plaintiffs Firm Over Ads
• Amgen Launches $5B Stock Buyback, Senior Notes Offering
• Allergan Faces Medicaid Fraud Probe By Mass. AG
• Jenner Reps General Dynamics' $360M Force Protection Buy
• AstraZeneca Asks Fed. Circ. To Bar Generic Crestor
• Simpson Aids JLL In $398M American Dental Purchase
• Lilly Wins First Zyprexa Liability Trial
• Top Legal Talent Take Center Stage In MF Global Suits
• Takeda Sued Again Over Diabetes Drug's Cancer Risks
• FDA Overrules Staff To Broaden Approval Of J&J's Xarelto
• Great Point Grabs Stake In Remote Radiology Startup
• Novartis Fights Actavis' Generic Dementia Patch
• EU Puts Spotlight On $21B J&J-Synthes Merger
• Acella Clears Up Medicis Acne Treatment Patent Suit
• Judge Nixes Last 2 Wrongful Death Suits In Digitek MDL
• 10th Circ. Upholds FDA Win In Morphine Exemption Suit
• Reed Smith Health Privacy Atty Jumps To King & Spalding
• Holding Rogue Employees Accountable Under The FCA
• GSK To Pay $3B To Settle US Avandia, Medicaid Probes
• Pharm Co. Breckenridge Sues Rivals Over Generic Laxative
• Cephalon Targets Breckenridge Over Nuvigil Patent
• Pharma Tech Co. Targets Rival Over Tracking Device IP
• Sandoz Settles Iowa, NY Drug Price Inflation Claims
• Adolor Investor Challenges Cubist's $415M Takeover Bid
• HSG Gene Sequence Patent Valid: UK High Court
• AXA Private Equity Carves Out Rhodia's Aspirin Unit
• Quinn Emanuel Adds Departing Novartis GC In Europe
• Express Scripts, Medco Deal Slammed By Small Biz Group
• Stiefel Will Get Split Trial For ERISA, Stock Fraud Claims
• Top Female Deal Maker: Shearman's Christa D'Alimonte
• Novartis Shakes Suit Over Bone Drug Warnings
• Olympus Committee To Probe Merger Fee Scandal